Jesus Lovera, MD
Neurology · New Orleans, LANPI 1336246107
Payments from drug & device makers
Across 614 payments — averaging $43.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$12K
- AbbVie$2K
- Biogen$2K
- EMD Serono, Inc.$2K
- TG Therapeutics, Inc.$984
- Novartis$948
- plus $6K from 42 others
What the payments were for
- Consulting fees$12,13346%
- Speaking & faculty fees$2001%
- Travel & lodging$1,3595%
- Food & beverage$12,73448%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,547 in reported general payments places this provider in the 85th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 199 | $1,831,387 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 53 | $512,454 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 43 | $451,295 |
| TysabriNatalizumab | 55 | $447,887 |
| OcrevusOcrelizumab | 11 | $407,741 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $332,768 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 21 | $246,822 |
| AubagioTeriflunomide | 26 | $240,707 |
| CopaxoneGlatiramer Acetate | 34 | $223,284 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 23 | $184,105 |
| TecfideraDimethyl Fumarate | 17 | $157,990 |
| BetaseronInterferon Beta-1b | 11 | $118,773 |
| GlatopaGlatiramer Acetate | 36 | $118,297 |
| Glatiramer Acetate | 52 | $112,319 |
| AmpyraDalfampridine | 20 | $111,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTysabri, Tecfidera, Avonex (4 Pack) | $2,151 | $711,61185 claims |
| Grifols USA, LLCGamunex-C | $12,371 | $512,45453 claims |
| PfizerPanzyga, Nurtec Odt, Lyrica | $38 | $364,21543 claims |
| CSL BehringPrivigen | $279 | $246,82221 claims |
| SanofiAubagio | $934 | $240,70726 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $358 | $223,28434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $41 | $4,24011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 neurology providers in Louisiana.
Other neurology in New Orleans
- Bridget BagertNew Orleans$1.4M
- Joseph TarsiaNew Orleans$1.2M
- Angela TraylorNew Orleans$941K
- Brian CopelandNew Orleans$304K
- John EnglandNew Orleans$268K
- Piotr OlejniczakNew Orleans$241K
- Sheryl Martin-SchildNew Orleans$106K
- Aimee AysenneNew Orleans$41K
- Caroline GoldinNew Orleans$38K
- Elizabeth CrabtreeNew Orleans$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.